title: Efficacy of edaravone in cardioembolic stroke.
abstract: OBJECTIVE
  We investigated the efficacy of edaravone in patients with cardioembolic stroke.
  
  
  METHODS
  Cardioembolic stroke patients were treated with drip intravenous infusion of edaravone (ED group, n=141) for 7 days, and were retrospectively compared with a historical-controlled cohort of similar patients (control group, n=114).
  
  
  RESULTS
  Early improvement (between day 0 and day 10), defined as change in National Institutes of Health Stroke Scale (NIHSS), was seen more frequently in mild patients (NIHSS on admission < or = 7) among the ED group than in the control group (change in NIHSS +2 vs. -2, respectively, p=0.013). Similar efficacy was not seen in the moderate to severe (NIHSS >7) patients. Independent patients (modified Rankin Scale < or = 2) 6 months after the onset were likely to be less frequent in the ED than the control group (28% versus 41%; p=0.066). Other clinical outcomes in the ED group were not significantly different from those in the control group.
  
  
  CONCLUSIONS
  The results suggest that edaravone may only be effective in mild patients with cardioembolic stroke.
authors.affiliation: Stroke Center, Saiseikai Kumamoto Hospital, Chikami.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Inatomi
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Takita
authors.forename: Toshiro
authors.initials: T
authors.lastname: Yonehara
authors.forename: Shodo
authors.initials: S
authors.lastname: Fujioka
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Teruyuki
authors.initials: T
authors.lastname: Hirano
authors.forename: Makoto
authors.initials: M
authors.lastname: Uchino
mesh_terms: D000368:Aged; D000983:Antipyrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy*; D003404:Creatinine / Q000097:blood; D000077553:Edaravone; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D016166:Free Radical Scavengers; D003404:Creatinine; D000077553:Edaravone; D000983:Antipyrine